| Literature DB >> 35269272 |
Tao Li1, Mingchao Sun1, Shaohua Wu1.
Abstract
Electrospun nanofiber materials have been considered as advanced dressing candidates in the perspective of wound healing and skin regeneration, originated from their high porosity and permeability to air and moisture, effective barrier performance of external pathogens, and fantastic extracellular matrix (ECM) fibril mimicking property. Gelatin is one of the most important natural biomaterials for the design and construction of electrospun nanofiber-based dressings, due to its excellent biocompatibility and biodegradability, and great exudate-absorbing capacity. Various crosslinking approaches including physical, chemical, and biological methods have been introduced to improve the mechanical stability of electrospun gelatin-based nanofiber mats. Some innovative electrospinning strategies, including blend electrospinning, emulsion electrospinning, and coaxial electrospinning, have been explored to improve the mechanical, physicochemical, and biological properties of gelatin-based nanofiber mats. Moreover, numerous bioactive components and therapeutic agents have been utilized to impart the electrospun gelatin-based nanofiber dressing materials with multiple functions, such as antimicrobial, anti-inflammation, antioxidation, hemostatic, and vascularization, as well as other healing-promoting capacities. Noticeably, electrospun gelatin-based nanofiber mats integrated with specific functions have been fabricated to treat some hard-healing wound types containing burn and diabetic wounds. This work provides a detailed review of electrospun gelatin-based nanofiber dressing materials without or with therapeutic agents for wound healing and skin regeneration applications.Entities:
Keywords: electrospinning; gelatin; nanofiber; skin regeneration; wound dressing
Year: 2022 PMID: 35269272 PMCID: PMC8911957 DOI: 10.3390/nano12050784
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Schematic of the design and development of bioactive and therapeutic agent loaded gelatin-based nanofiber mats for wound treatment applications.
Figure 2Summarization of some representative innovative platforms and dressing materials and Schematic of the representative concept and mechanisms of a wound healing process using an advanced dressing material. Reprinted with permission from ref. [45], Elsevier, 2019.
Figure 3(A) Schematic of a conventional electrospinning device. (B) Schematic of some representative modified electrospinning strategies to control the composition and structure of electrospun fibers.
Lists of some representative polymers blending with gelatin for electrospinning.
| Polymers Blending with Gelatin | Solvent | Mean Fiber | Young’s Modulus (MPa) | Ultimate | Ref. |
|---|---|---|---|---|---|
| Fibrinogen | HFIP | 133–309 | Dry: 0.83–2.5 | Dry: 0.061–1.2 | [ |
| Zein | 70% ( | 423–910 | / | Dry: 0.2–6.3 | [ |
| Zein | 80% ( | 380–696 | Dry: 72.1 | / | [ |
| Zein | HFIP | 69–950 | / | / | [ |
| HA | Dimethyl Formamide (DMF)/water (0.5–2, | 190–500 | / | / | [ |
| CS | TFA | 90–279 | / | / | [ |
| CS | TFA/dichloromethane (DCM) (7/3, | 180–196 | / | Dry: 1.05–1.28 | [ |
| CS | TFA | 120–220 | / | Dry: 37.91 | [ |
| CA | HFIP | 198–266 | Dry: 47.92–95.44 | Dry: 1.59–3.06 | [ |
| PDL-CL | HFIP | 305 | / | / | [ |
| PCL | TFE | 10–1000 | Dry: 30.8 | Dry: 1.29 | [ |
| PCL | TFE | 200–800 | / | / | [ |
| PCL | TFE | 300–600 | / | / | [ |
| PCL | chloroform/methanol (3/1, | 291–1173 | / | / | [ |
| PCL | 80% ( | 444 | / | / | [ |
| PLA | HFIP | 230–360 | / | / | [ |
| PLLA | HFIP | 67–85 | / | / | [ |
| PLLA | HFIP | 200–2100 | Dry: 42.45–48.76 | Dry: 2.45–3.48 | [ |
| PLLA | DCM/DMF (65/35 | 500–560 | Dry: 253–621 | Dry: 6.0–12 | [ |
| PGA | HFIP | 133–863 | Dry: 32–72 | Dry: 0.65–1.9 | [ |
| PLGA | TFE | 479–774 | Dry: 0.29–0.96 | Dry: 1.44–3.59 | [ |
| PLGA | HFIP | 500–1700 | Dry: 81–101 | / | [ |
| PU | HFIP | 400–2100 | Dry: 21.9–620.6 | Dry: 11.5–13.7 | [ |
| PMETAC | formic acid/acetic acid (3/1, | 429–2410 | / | / | [ |
| Nylon 6 | formic acid and acetic acid (4/1, wt) | ~10 | / | / | [ |
| PVA | Water | 90–290 | / | / | [ |
Figure 4(A) Schematic illustration of the design of gelatin-PAMAM dendrimer G3.5 conjugates. (B) 1H-NMR of gelatin (Gel) and MeGel. The MeGel was synthesized by the methacryloyl substitution of Gel. (C) Schematic illustration of the construction of crosslinked MeGel/PLLA electrospun nanofiber mats by combining blend electrospinning with subsequent UV crosslinking process. (A) Reprinted with permission from ref [122], ACS Publications, 2013. (B,C) Reprinted with permission from ref [76], MDPI, 2022.
Figure 5Design and development of composite wound dressings containing both CS-gelatin (Gel) nanofibers and CS-HA nanofibers. (A) Fluorescent images of (a) CS-Gel nanofiber mats with green color, (b) CS-HA nanofiber mats with red color and (c) merged CS-Gel/CS-HA nanofiber mats. (B) Photographs of wound-healing process using different dressings, i.e., CS nanofiber mats, CS-Gel nanofiber mats, CS-Gel/HA nanofiber mats, and medical gauzes (Control). (C) Statistical analysis of wound area of different experimental groups at predetermined time points. * p < 0.05 compared to control. # p < 0.05 compared to CS-Gel group. Reprinted with permission from ref. [129], Elsevier, 2020.
Figure 6Design and development of a novel 3D electrospun gelatin nanofiber sponge as rapid hemostasis materials. (A) Photograph of the as-prepared 3D electrospun gelatin nanofiber sponge standing on a leaf. (B) Photographs of compress and recovery of gelatin nanofiber sponge with different degrees of external forces. (C) Schematic of an in vivo liver trauma model and an ear artery injury model using rabbit. (D) Photographs of hemostasis based on the two different injury models using four different samples. Membrane: electrospun 2D gelatin nanofiber mat; Sponge: 3D electrospun gelatin nanofiber sponge; Commercial: commercial 3D gelatin nonfibrous hemostatic sponge; Gauze: Commonly used medical gauze. (E) hemostasis time and (F) Blood loss of four different material groups based on the ear artery injury model. (G) hemostasis time and (H) Blood loss of four different material groups based on the liver trauma model. * p < 0.05, ** p < 0.01. Reprinted with permission from ref. [132], Wiley, 2021.
Figure 7Design and development of in situ gelatin/PLA nanofiber wound dressings by using a 3D printed handheld electrospinning device. (A) Design and fabrication of 3D printed and handheld electrospinning device for gelatin/PLA blend electrospinning. (a) Schematic illustration of the application of in situ gelatin/PLA nanofiber dressing for wound covering and healing; (b) Computer-aided design of the electrospinning hand-holder; (c) Photograph of the 3D printed handheld electrospinning device; (d) Circuit design of the electrospinning setup; (e) Photograph of the finally generated handheld electrospinning setup. (B) In situ repair of the acute injury wounds using mouse models. (a) A series of photographs using in situ electrospun gelatin/PLA nanofibers to cover the wound; (b) Photographs of mouse wounds after covering or not; (c) A series of photographs of mouse wound after in situ treatment using electrospun gelatin/PLA nanofiber mat; (d) Photographs of regenerated skins after 8 weeks of treatment using electrospun gelatin/PLA nanofiber mat; (e) Photographs of regenerated skins after 8 weeks of treatment using commercial gauze. Reprinted with permission from ref. [133], Frontiers, 2021.
Lists of some representative bioactive and therapeutic components introduced into electrospun gelatin-based nanofiber mats for wound treatment.
| Materials | Bioactive Agent | Biological Performances | Animal Model | Ref. |
|---|---|---|---|---|
| Gelatin/PVA | Pine honey | Antioxidant | None | [ |
| Gelatin/CS | Cinnamon | Antibacterial | None | [ |
| Gelatin/PCL | Cinnamon | Antibacterial; Promoting wound healing | Acute injury wound with a square of 15 mm × 15 mm | [ |
| Gelatin | Centella asiatica extract | Antibacterial; Promoting fibroblast proliferation and collagen synthesis; Accelerating wound healing | Acute injury wound with a square of 20 mm × 20 mm | [ |
| Gelatin/Starch | Lawsonia Inermis (henna) | Antibacterial; Anti-inflammatory; Treating burn wound infections | Second-degree burn wound (A circle with a diameter of 5 mm) | [ |
| Gelatin/PCL | Lawsone (2-hydroxy-1,4-naphthoquinone) | Antibacterial; Anti-inflammatory; Promoting wound healing | Acute injury wound with a circular area of 1.8 mm2 | [ |
| Gelatin/CA | Zataria multiflora | Antioxidant; Anti-inflammatory; Antibacterial; Accelerating wound healing | Second-degree burn wound with a square of 20 mm × 20 mm | [ |
| Gelatin | Cinnamaldehyde (CEO), or Limonene (LEO), or Eugenol (EEO) | Radical scavenging; Antibacterial | None | [ |
| Gelatin/PLGA | Hypericum capitatum var. capitatum (HCC) extract | Antibacterial | None | [ |
| Gelatin/PCL | Clove essential oil | Antibacterial | None | [ |
| Gelatin/PVA | Carica papaya | Antibacterial; Anti-inflammatory | None | [ |
| Gelatin/PCL | Oregano oil | Antibacterial | None | [ |
| Gelatin | Chondroitin sulfate | ECM mimicking; Promoting wound healing | Acute injury wound (a circular with a diameter of 15 mm) | [ |
| Gelatin/PCL | Trimethoxysilylpropyl octadecyldimethyl ammonium chloride (QAS) | Cationic antibacterial agent; | None | [ |
| Gelatin/Silk fibroin (SF) | Astragaloside IV | Anti-scar; Accelerating wound healing | Second-degree burn wound | [ |
| Gelatin/SF | Astragaloside IV | Anti-scar; Accelerating wound healing | Acute injury wound with a square of 15 mm × 15 mm | [ |
| Gelatin/PCL | (+)-catechin | Antioxidant; scavenging reactive oxygen species (ROS) | None | [ |
| Gelatin/PCL | Ketoprofen | Anti-inflammatory | None | [ |
| Gelatin/PCL | Taurine (2-aminoethane sulfonic acid) | Non-essential sulfur-containing | Acute injury wound with a square of 15 mm × 15 mm | [ |
| Gelatin/PLA | Ciprofloxacin | Broad-spectrum antibacterial; Treating infectious diseases | None | [ |
| Gelatin/PVA | Gentamicin | Accelerating the wound healing; Reducing the treatment duration | Acute injury wound (a circular with a diameter of 8 mm) | [ |
| Gelatin/PCL/ZIF-8 | Gentamicin | Antibacterial; Accelerating the wound healing | Acute injury wound (a circular with a diameter of 20 mm) | [ |
| MeGel/PCL | Cephalexin | Antibacterial; Improving re-epithelialization; Promoting collagen deposition | Second-degree burn wound (A circular with a diameter of 5 mm) | [ |
| Gelatin/PVA | Cephradine | Broad-spectrum antibiotic (particularly against Gram-positive bacteria); Accelerating the wound healing process | Diabetic wound with a Ceph-resistant S. aureus infection (a circular with a diameter of 7 mm) | [ |
| Gelatin/SF | Ceftazidime | Antibacterial; Preventing post-surgical adhesion | None | [ |
| Gelatin/PLGA | Liraglutide | Promoting vascularization; Accelerating wound healing | Acute injury wound (a circular with a diameter of 20 mm) | [ |
| Gelatin/PU | Silver-Sulfadiazine | Topical treatment for burn wound in clinics; Preventing burn infection; Promoting wound healing | Second-degree burn wound (A circular with a diameter of 15 mm) | [ |
| Gelatin/Polyhydroxy butyric acid (PHB) | Silver-Sulfadiazine | Supporting enhanced re-epithelialization and MMP-9 production; Accelerating wound healing | Second-degree burn wound | [ |
| Gelatin | Vitamins A and E | Antibacterial; Promoting the proliferation and collagen-specific gene expression of fibroblasts; Accelerating wound healing | Acute injury wound with a square of 30 mm × 30 mm | [ |
| Gelatin/PLA | Epidermal growth factor (EGF) | Antibacterial; Anti-inflammatory; Promoting re-epithelialization; shortening healing time in venous ulcers | Second-degree burn wound (A circular with a diameter of 4 mm) | [ |
| Heparin/Gelatin/PCL | Basic fibroblast growth factor (bFGF) | Promoting angiogenesis; | Acute injury wound (a circular with a diameter of 10 mm) | [ |
Figure 8Design and development of dual-drugs loaded electrospun gelatin-based nanofiber mats for wound treatment. (A) Schematic illustration of the construction and working mechanisms of novel electrospinning double-layered PCL/gelatin nanofiber dressing. The above layer and bottom layer were made from amoxicillin loaded PCL/gelatin nanofibers and ZnO nanoparticles loaded PCL/gelatin nanofibers, respectively. (B) Cumulative release curves of quercetin and ciprofloxacin hydrochloride loaded electrospun PCL/gelatin nanofiber mats. (C) Cumulative release curves of EGCG from two different carriers. PGEB: EGCG directedly loaded PLCL/gelatin nanofiber mats; PGEC: EGCG-PLCL/gelatin core-sheath nanofiber mats. (D) Cumulative release curves of curcumin from three different carriers. NCs/Cur: curcumin loaded CS nanoparticles; PCL/Gela/Cur: curcumin loaded PCL/gelatin nanofibers: PCL/Gela/NCs/Cur: curcumin loaded CS nanoparticles were further encapsulated into PCL/gelatin nanofibers. (E) Regeneration of rabbit wound by using human urine-derived stem cells (hUSCs)-seeded electrospun PCL/gelatin nanofiber dressings. Ctrl: Untreated control group; PCL-GT: PCL/gelatin nanofiber dressing; USCs-PCL-GT: hUSCs-seeded PCL/gelatin nanofiber dressing. (a) Actual photographs of wound sites on day 0 and day 14. Statistical analysis for (b) wound closure ratio and (c) collagen area ratio on day 14. * p < 0.05, *** p < 0.01. (F) HE stained images from the wound sites treated with human placenta-derived mesenchymal stem cells (hPDMSCs)-carried electrospun gelatin nanofiber mats containing platelet-rich plasma (PRP). (a) Before treatment. (b) After two weeks of treatment. (c) After six weeks of treatment. (A) Reprinted with permission from ref. [165], Elsevier, 2020. (B) Reprinted with permission from ref. [166], Elsevier, 2019. (C) Reprinted with permission from ref. [168], Elsevier, 2022. (D) Reprinted with permission from ref. [169], Elsevier, 2020. (E) Reprinted with permission from ref. [170], Springer Nature, 2014. (F) Reprinted with permission from ref. [171], Elsevier, 2021.